Clinical Trials Using Cisplatin

Clinical trials are research studies that involve people. The clinical trials on this list are studying Cisplatin. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 176-180 of 180
< Previous 1 ... 6 7 8

  • Pembrolizumab in Treating Patients with Malignant Pleural Mesothelioma That Can Be Removed by Surgery

    This pilot phase I trial studies pembrolizumab in treating patients malignant pleural mesothelioma that can be removed by surgery. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.
    Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois

  • Radiation Therapy with Cisplatin, Docetaxel, or Cetuximab and Docetaxel after Surgery in Treating Patients with High-Risk Stage III-IV Squamous Cell Head and Neck Cancer

    This randomized phase II / III trial studies how well radiation therapy works when given together with cisplatin, docetaxel or cetuximab and docetaxel after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab may block the growth of tumor cells by blocking a protein and many other tumor cells functions. It is not yet known whether radiation therapy is more effective when given with cisplatin, docetaxel, or cetuximab and docetaxel.
    Location: 172 locations

  • Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients with Soft Tissue or Bone Sarcoma Metastatic to the Lungs

    This phase I / II trial studies the side effects of pulmonary suffusion in controlling minimal residual disease in patients with soft tissue or bone sarcoma that has spread to the lungs. Pulmonary suffusion is a minimally invasive delivery of chemotherapeutic agents like cisplatin to lung tissues. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Pulmonary suffusion may also be useful in avoiding later use of drugs by vein that demonstrate no effect on tumors when delivered locally.
    Location: Roswell Park Cancer Institute, Buffalo, New York

  • Pre-treatment Biopsy Results in Predicting Response in Patients with Metastatic or Recurrent Triple Negative Breast Cancer after Treatment with Cisplatin and Radiation Therapy

    This phase II trial studies how well the results of a pre-treatment biopsy work in predicting response in patients with triple negative breast cancer that has spread to other parts of the body (metastatic) or has come back after treatment (recurrent) with cisplatin and radiation therapy. A biopsy is where a tissue is removed from the body and examined under a microscope to determine whether disease is present. Studying tissue collected during pre-treatment biopsies in the laboratory may help determine the ability of the tumor to repair itself after being treated with chemotherapy (cisplatin) and radiation therapy and predict how well these treatments work for future patients with triple negative breast cancer.
    Location: 7 locations

  • A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)

    This study will evaluate PF-05212384 (gedatolisib) PI3K / mTOR inhibitor)) in combination with either docetaxel, cisplatin or dacomitinib in select advanced solid tumors. The study will assess the safety, pharmacokinetics and pharmacodynamics of these combinations in patients with advanced cancer in order to determine the maximum tolerated dose in each combination. The cisplatin combination expansion portion will evaluate the anti tumor activity of PF 05212384 plus cisplatin in patients with TNBC in 2 separate Arms (Arm 1 and Arm 2).
    Location: See Clinical

< Previous 1 ... 6 7 8